EMA accepts application of Eisai for two additional indications of anticancer agent lenvatinib in combination with pembrolizumab
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted ...
Read more
Tag: Eisai
